Review



heca 452 mab anti sle x  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier
Bioz Manufacturer Symbol Bio-Rad manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Bio-Rad heca 452 mab anti sle x
    Heca 452 Mab Anti Sle X, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 151 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/heca+452+mab+anti+sle+x/Lyphochek+Therapeutic+Drug+Monitoring+Control+(TDM)/pmc02574550-297-24-11
    Average 93 stars, based on 151 article reviews
    heca 452 mab anti sle x - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin
    Article Snippet: Solubilized protein was diluted in a reducing sample buffer and separated on 4–20% Criterion TM SDS–PAGE gradient gels (Bio-Rad). .. Resolved proteins were immunoblotted onto Criterion Gel TM polyvinylidene difluoride membranes (Bio-Rad), blocked in FBS for 1 h at 22°C, and then incubated with HECA-452 mAb anti-sLe X (1 μg/mL), isotype control rat IgM, mouse E-selectin-Ig chimera (1 μg/mL) (R&D Systems), isotype control human IgG (1 μg/mL), or mouse IgG anti-β-actin (1 μg/mL) for 1 h at 37°C. .. Blots were then washed three times with Tris-buffered saline and 0.1% Tween-20, incubated with alkaline phosphatase (AP)-conjugated rabbit anti-rat IgM, AP-anti-human IgG, or AP-anti-mouse IgG (all at 1:1000; Zymed Laboratories, Inc., San Francisco, CA) for 1 h at 22°C, and washed three times for 15 min each with Tris-buffered saline and 0.1% Tween-20.

    Control:

    Article Title: Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin
    Article Snippet: Solubilized protein was diluted in a reducing sample buffer and separated on 4–20% Criterion TM SDS–PAGE gradient gels (Bio-Rad). .. Resolved proteins were immunoblotted onto Criterion Gel TM polyvinylidene difluoride membranes (Bio-Rad), blocked in FBS for 1 h at 22°C, and then incubated with HECA-452 mAb anti-sLe X (1 μg/mL), isotype control rat IgM, mouse E-selectin-Ig chimera (1 μg/mL) (R&D Systems), isotype control human IgG (1 μg/mL), or mouse IgG anti-β-actin (1 μg/mL) for 1 h at 37°C. .. Blots were then washed three times with Tris-buffered saline and 0.1% Tween-20, incubated with alkaline phosphatase (AP)-conjugated rabbit anti-rat IgM, AP-anti-human IgG, or AP-anti-mouse IgG (all at 1:1000; Zymed Laboratories, Inc., San Francisco, CA) for 1 h at 22°C, and washed three times for 15 min each with Tris-buffered saline and 0.1% Tween-20.



    Similar Products

    anti-sle x mab (heca-452  (Becton Dickinson)
    90
    Becton Dickinson anti-sle x mab (heca-452
    Measurement of UDP-GlcNAc level in extracts of <t>4-F-GlcNAc-treated</t> <t>sLe</t> <t>X</t> (+) KG1a and T cells. a , chair configurations of 4-F-GlcNAc (peracetylated) and structurally related control analogs, UDP-GlcNAc, GlcNAc, α-Glc pentaacetate, and 4-F-α-GlcNAc (unacetylated). b , assay specificity for detecting the sugars shown in a. c and d , level of UDP-GlcNAc measured in sLe X (+) KG1a or T cell extracts. KG1a cells were incubated for 48 h with 0.05 m m sugars. T cells were incubated for 48 h with 0.05 m m sugars or for 38 h with 0.01–0.025 m m 4-F-GlcNAc (peracetylated). Shown is mean UDP-GlcNAc level with S.E. indicated when compared with untreated control. Experiments were performed in triplicate on at least three separate occasions and donors. Statistically significant differences compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001, one-way analysis of variance with Dunnett's post hoc test.
    Anti Sle X Mab (Heca 452, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/heca+452+mab+anti+sle+x/heca+452+antibody/pmc03122228-40-0-7
    Average 90 stars, based on 1 article reviews
    anti-sle x mab (heca-452 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    anti-sle x mab heca-452  (Becton Dickinson)
    90
    Becton Dickinson anti-sle x mab heca-452
    Measurement of UDP-GlcNAc level in extracts of <t>4-F-GlcNAc-treated</t> <t>sLe</t> <t>X</t> (+) KG1a and T cells. a , chair configurations of 4-F-GlcNAc (peracetylated) and structurally related control analogs, UDP-GlcNAc, GlcNAc, α-Glc pentaacetate, and 4-F-α-GlcNAc (unacetylated). b , assay specificity for detecting the sugars shown in a. c and d , level of UDP-GlcNAc measured in sLe X (+) KG1a or T cell extracts. KG1a cells were incubated for 48 h with 0.05 m m sugars. T cells were incubated for 48 h with 0.05 m m sugars or for 38 h with 0.01–0.025 m m 4-F-GlcNAc (peracetylated). Shown is mean UDP-GlcNAc level with S.E. indicated when compared with untreated control. Experiments were performed in triplicate on at least three separate occasions and donors. Statistically significant differences compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001, one-way analysis of variance with Dunnett's post hoc test.
    Anti Sle X Mab Heca 452, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/heca+452+mab+anti+sle+x/heca+452+antibody/pmc02920724-102-2-9
    Average 90 stars, based on 1 article reviews
    anti-sle x mab heca-452 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    heca 452 mab anti sle x  (Bio-Rad)
    93
    Bio-Rad heca 452 mab anti sle x
    Measurement of UDP-GlcNAc level in extracts of <t>4-F-GlcNAc-treated</t> <t>sLe</t> <t>X</t> (+) KG1a and T cells. a , chair configurations of 4-F-GlcNAc (peracetylated) and structurally related control analogs, UDP-GlcNAc, GlcNAc, α-Glc pentaacetate, and 4-F-α-GlcNAc (unacetylated). b , assay specificity for detecting the sugars shown in a. c and d , level of UDP-GlcNAc measured in sLe X (+) KG1a or T cell extracts. KG1a cells were incubated for 48 h with 0.05 m m sugars. T cells were incubated for 48 h with 0.05 m m sugars or for 38 h with 0.01–0.025 m m 4-F-GlcNAc (peracetylated). Shown is mean UDP-GlcNAc level with S.E. indicated when compared with untreated control. Experiments were performed in triplicate on at least three separate occasions and donors. Statistically significant differences compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001, one-way analysis of variance with Dunnett's post hoc test.
    Heca 452 Mab Anti Sle X, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/heca+452+mab+anti+sle+x/Lyphochek+Therapeutic+Drug+Monitoring+Control+(TDM)/pmc02574550-297-24-11
    Average 93 stars, based on 1 article reviews
    heca 452 mab anti sle x - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    heca-452 mab anti-sle x (1 μg/ml)  (R&D Systems)
    90
    R&D Systems heca-452 mab anti-sle x (1 μg/ml)
    Measurement of UDP-GlcNAc level in extracts of <t>4-F-GlcNAc-treated</t> <t>sLe</t> <t>X</t> (+) KG1a and T cells. a , chair configurations of 4-F-GlcNAc (peracetylated) and structurally related control analogs, UDP-GlcNAc, GlcNAc, α-Glc pentaacetate, and 4-F-α-GlcNAc (unacetylated). b , assay specificity for detecting the sugars shown in a. c and d , level of UDP-GlcNAc measured in sLe X (+) KG1a or T cell extracts. KG1a cells were incubated for 48 h with 0.05 m m sugars. T cells were incubated for 48 h with 0.05 m m sugars or for 38 h with 0.01–0.025 m m 4-F-GlcNAc (peracetylated). Shown is mean UDP-GlcNAc level with S.E. indicated when compared with untreated control. Experiments were performed in triplicate on at least three separate occasions and donors. Statistically significant differences compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001, one-way analysis of variance with Dunnett's post hoc test.
    Heca 452 Mab Anti Sle X (1 μg/Ml), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/heca+452+mab+anti+sle+x/heca+452+mab+anti+sle+x++1+%CE%BCg+ml+/pmc02574550-297-24-39
    Average 90 stars, based on 1 article reviews
    heca-452 mab anti-sle x (1 μg/ml) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Measurement of UDP-GlcNAc level in extracts of 4-F-GlcNAc-treated sLe X (+) KG1a and T cells. a , chair configurations of 4-F-GlcNAc (peracetylated) and structurally related control analogs, UDP-GlcNAc, GlcNAc, α-Glc pentaacetate, and 4-F-α-GlcNAc (unacetylated). b , assay specificity for detecting the sugars shown in a. c and d , level of UDP-GlcNAc measured in sLe X (+) KG1a or T cell extracts. KG1a cells were incubated for 48 h with 0.05 m m sugars. T cells were incubated for 48 h with 0.05 m m sugars or for 38 h with 0.01–0.025 m m 4-F-GlcNAc (peracetylated). Shown is mean UDP-GlcNAc level with S.E. indicated when compared with untreated control. Experiments were performed in triplicate on at least three separate occasions and donors. Statistically significant differences compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001, one-way analysis of variance with Dunnett's post hoc test.

    Journal: The Journal of Biological Chemistry

    Article Title: Peracetylated 4-Fluoro-glucosamine Reduces the Content and Repertoire of N - and O -Glycans without Direct Incorporation *

    doi: 10.1074/jbc.M110.194597

    Figure Lengend Snippet: Measurement of UDP-GlcNAc level in extracts of 4-F-GlcNAc-treated sLe X (+) KG1a and T cells. a , chair configurations of 4-F-GlcNAc (peracetylated) and structurally related control analogs, UDP-GlcNAc, GlcNAc, α-Glc pentaacetate, and 4-F-α-GlcNAc (unacetylated). b , assay specificity for detecting the sugars shown in a. c and d , level of UDP-GlcNAc measured in sLe X (+) KG1a or T cell extracts. KG1a cells were incubated for 48 h with 0.05 m m sugars. T cells were incubated for 48 h with 0.05 m m sugars or for 38 h with 0.01–0.025 m m 4-F-GlcNAc (peracetylated). Shown is mean UDP-GlcNAc level with S.E. indicated when compared with untreated control. Experiments were performed in triplicate on at least three separate occasions and donors. Statistically significant differences compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001, one-way analysis of variance with Dunnett's post hoc test.

    Article Snippet: Anti-sLe X mAb (HECA-452) was purchased from BD PharMingen, Inc. (San Diego, CA).

    Techniques: Incubation

    Analysis of 4-F-GlcNAc efficacy on E-selectin and Gal-1 ligand expression on sLe X KG1a cells. a , Western blots of KG1a cells treated with diluent control ( Untreated ), 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 ( E-sel.-hFc ) (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or anti-β-actin mAb (1 μg/ml). b , using NIH ImageJ, densitometric gray scale units of scanned lanes from 50 to 260 kDa of triplicate Western blots were measured and plotted as mean ± S.D. ( error bars ) in relative gray units. c , flow cytometry of KG1a cells treated with diluent control ( Untreated ), 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or respective isotype control and respective fluorophore-conjugated secondary antibody. d , mean fluorescent intensities from triplicate flow cytometry experiments were compared with untreated control and presented as percentage of untreated control. Statistically significant differences when compared with untreated controls are shown as follows. **, p < 0.01; ***, p < 0.001.

    Journal: The Journal of Biological Chemistry

    Article Title: Peracetylated 4-Fluoro-glucosamine Reduces the Content and Repertoire of N - and O -Glycans without Direct Incorporation *

    doi: 10.1074/jbc.M110.194597

    Figure Lengend Snippet: Analysis of 4-F-GlcNAc efficacy on E-selectin and Gal-1 ligand expression on sLe X KG1a cells. a , Western blots of KG1a cells treated with diluent control ( Untreated ), 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 ( E-sel.-hFc ) (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or anti-β-actin mAb (1 μg/ml). b , using NIH ImageJ, densitometric gray scale units of scanned lanes from 50 to 260 kDa of triplicate Western blots were measured and plotted as mean ± S.D. ( error bars ) in relative gray units. c , flow cytometry of KG1a cells treated with diluent control ( Untreated ), 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or respective isotype control and respective fluorophore-conjugated secondary antibody. d , mean fluorescent intensities from triplicate flow cytometry experiments were compared with untreated control and presented as percentage of untreated control. Statistically significant differences when compared with untreated controls are shown as follows. **, p < 0.01; ***, p < 0.001.

    Article Snippet: Anti-sLe X mAb (HECA-452) was purchased from BD PharMingen, Inc. (San Diego, CA).

    Techniques: Expressing, Western Blot, Staining, Flow Cytometry

    Analysis of 4-F-GlcNAc efficacy on E-selectin and Gal-1 ligand expression on sLe X (+) T cells. a , Western blots of T cells treated with diluent control ( Untreated ), 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 ( E-sel.-hFc ) (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or anti-β-actin mAb (1 μg/ml). b , using NIH ImageJ, densitometric gray scale units of scanned lanes from 50 to 260 kDa of triplicate Western blots were measured and plotted as mean ± S.D. ( error bars ) in relative gray units. c , flow cytometry of T cells treated with diluent control, 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or the respective isotype control and respective fluorophore-conjugated secondary antibody. d , mean fluorescent intensities from triplicate flow cytometry experiments were compared with untreated control and presented as percentage of untreated control. Statistically significant differences when compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

    Journal: The Journal of Biological Chemistry

    Article Title: Peracetylated 4-Fluoro-glucosamine Reduces the Content and Repertoire of N - and O -Glycans without Direct Incorporation *

    doi: 10.1074/jbc.M110.194597

    Figure Lengend Snippet: Analysis of 4-F-GlcNAc efficacy on E-selectin and Gal-1 ligand expression on sLe X (+) T cells. a , Western blots of T cells treated with diluent control ( Untreated ), 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 ( E-sel.-hFc ) (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or anti-β-actin mAb (1 μg/ml). b , using NIH ImageJ, densitometric gray scale units of scanned lanes from 50 to 260 kDa of triplicate Western blots were measured and plotted as mean ± S.D. ( error bars ) in relative gray units. c , flow cytometry of T cells treated with diluent control, 0.05 m m 4-F-GlcNAc, or 4-F-GlcNAc and bromelain were stained with mouse E-selectin-human IgG Fc1 (1 μg/ml), Gal-1hFc (10 μg/ml), anti-sLe X mAb (1 μg/ml), anti-PSGL-1 mAb (1 μg/ml), or the respective isotype control and respective fluorophore-conjugated secondary antibody. d , mean fluorescent intensities from triplicate flow cytometry experiments were compared with untreated control and presented as percentage of untreated control. Statistically significant differences when compared with untreated controls are shown as follows. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

    Article Snippet: Anti-sLe X mAb (HECA-452) was purchased from BD PharMingen, Inc. (San Diego, CA).

    Techniques: Expressing, Western Blot, Staining, Flow Cytometry

    Gene expression analysis of 4-F-GlcNAc-treated sLe X (+) KG1a and T cells. a , heat maps of differentially expressed gene transcripts from untreated versus 4-F-GlcNAc-treated KG1a cells and untreated versus 4-F-GlcNAc-treated T cells depict increased ( red ) and decreased ( blue ) expression relative to the mean transcript expression values. At FC of 4-F-GlcNAc-treated/untreated ratios greater than 1.4, there were 17 and 94 differentially expressed gene transcripts from KG1a and T cells, respectively (adjusted p value of <0.1). b , gene expression clustering from untreated and 4-F-GlcNAc-treated KG1a and T cells of triplicate experiments was validated using centered correlation and average linkage and is represented in a dendrogram. c , a Venn diagram demonstrated that five genes were similarly modulated in KG1a and T cells (adjusted p value of <0.15).

    Journal: The Journal of Biological Chemistry

    Article Title: Peracetylated 4-Fluoro-glucosamine Reduces the Content and Repertoire of N - and O -Glycans without Direct Incorporation *

    doi: 10.1074/jbc.M110.194597

    Figure Lengend Snippet: Gene expression analysis of 4-F-GlcNAc-treated sLe X (+) KG1a and T cells. a , heat maps of differentially expressed gene transcripts from untreated versus 4-F-GlcNAc-treated KG1a cells and untreated versus 4-F-GlcNAc-treated T cells depict increased ( red ) and decreased ( blue ) expression relative to the mean transcript expression values. At FC of 4-F-GlcNAc-treated/untreated ratios greater than 1.4, there were 17 and 94 differentially expressed gene transcripts from KG1a and T cells, respectively (adjusted p value of <0.1). b , gene expression clustering from untreated and 4-F-GlcNAc-treated KG1a and T cells of triplicate experiments was validated using centered correlation and average linkage and is represented in a dendrogram. c , a Venn diagram demonstrated that five genes were similarly modulated in KG1a and T cells (adjusted p value of <0.15).

    Article Snippet: Anti-sLe X mAb (HECA-452) was purchased from BD PharMingen, Inc. (San Diego, CA).

    Techniques: Expressing